Skip to main content
logo
Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
9.45
+0.44 (4.83%)
Aug 28, 2026, 3:13 PM EDT - Market open

Akari Therapeutics, Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
181332183571
Market Cap Growth
-34.44%-59.03%83.11%-49.58%-51.00%0.31%
Enterprise Value
111331102758
Last Close Price
9.0111.5648.80124.80375.921200.00

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
0.850.471.45-77.0219.5312.85
P/TBV Ratio
----19.7212.91

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.040.030.15---
Net Debt / Equity Ratio
-0.38-0.160.0316.79-7.40-1.68
Net Debt / EBITDA Ratio
-0.37-0.040.230.570.54
Net Debt / FCF Ratio
0.650.42-0.050.230.620.50
Quick Ratio
0.550.420.130.841.101.54
Current Ratio
0.600.440.150.951.151.91
Return on Equity (ROE)
-140.09%-68.43%-179.92%-1281.43%-483.23%-233.27%
Return on Assets (ROA)
-19.10%-15.36%-37.89%-115.51%-113.26%-81.96%
Return on Capital Employed (ROCE)
-55.40%-34.00%-54.30%7338.90%-1289.10%-309.90%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-176.49%-130.73%-61.28%-56.74%-50.73%-24.40%
FCF Yield
-61.33%-79.87%-38.87%-93.17%-61.47%-26.40%
Buyback Yield / Dilution
-128.91%-181.85%-144.03%-56.79%-45.46%-35.87%
SEC Filings: 10-K · 10-Q